CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms bas...
Phase 2
Birmingham, Alabama, United States and 12 other locations
avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...
Phase 2
Birmingham, Alabama, United States and 11 other locations
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
Birmingham, Alabama, United States of America and 176 other locations
monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...
Phase 2
Birmingham, Alabama, United States and 140 other locations
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It wi ...
Phase 1
Birmingham, Alabama, United States and 41 other locations
in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estro ...
Phase 2
Birmingham, Alabama, United States and 11 other locations
tumors....
Phase 1
Birmingham, Alabama, United States and 7 other locations
to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast...
Phase 2
Birmingham, Alabama, United States and 10 other locations
and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab to subjects with advanced solid tumors....
Phase 1
Birmingham, Alabama, United States and 94 other locations
followed by immunotherapy, for patients with brain metastases from triple negative or BRCA-mutated breast cancers...
Phase 1, Phase 2
Birmingham, Alabama, United States and 6 other locations
Clinical trials
Research sites
Resources
Legal